Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1982 5
1983 5
1984 7
1985 5
1986 3
1987 2
1988 3
1989 1
1990 12
1991 4
1992 4
1993 3
1994 9
1995 10
1996 7
1997 12
1998 14
1999 11
2000 20
2001 16
2002 18
2003 22
2004 34
2005 31
2006 34
2007 30
2008 39
2009 33
2010 37
2011 40
2012 39
2013 42
2014 32
2015 45
2016 56
2017 57
2018 62
2019 62
2020 61
2021 54
2022 64
2023 64
2024 51

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,048 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lung Small Cell Carcinoma"
Page 1
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
PURPOSE: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to …
PURPOSE: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) …
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Carpenter EL, Langer CJ, Wherry EJ, Minn AJ. Mathew D, et al. Science. 2024 Jun 21;384(6702):eadf1329. doi: 10.1126/science.adf1329. Epub 2024 Jun 21. Science. 2024. PMID: 38900877 Free PMC article. Clinical Trial.
We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD-1 (programmed cell death protein 1) immunotherapy improves immune function and antitumor responses in mice and results in high response rates (67%) in a phase 2 clinical t …
We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD-1 (programmed cell death protein 1) immun …
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. Owen DH, et al. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. J Hematol Oncol. 2019. PMID: 31215500 Free PMC article. Review.
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually relapse, and very few patients survive more t …
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response …
Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y, Chen K, Fan Y. Yu Y, et al. Int J Cancer. 2023 Jun 1;152(11):2243-2256. doi: 10.1002/ijc.34346. Epub 2022 Nov 29. Int J Cancer. 2023. PMID: 36346100 Review.
Extensive-stage small-cell lung cancer (ES-SCLC) is regarded as a refractory carcinoma associated with extremely rapid disease progression. ...Further studies have extensively evaluated small-molecule antiangiogenic drugs, PARP inhibitors …
Extensive-stage small-cell lung cancer (ES-SCLC) is regarded as a refractory carcinoma associated with ex …
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341578 Clinical Trial.
Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 editing of immune checkpoint genes could improve the efficacy of T cell therapy, but the first necessary undertaking is to understand the safety and feasibility. Here, we report results from a first-in …
Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 editing of immune checkpoint genes could improve the efficacy of T …
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K, Naidoo J, Lin CT, Danoff S. Suresh K, et al. Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4. Chest. 2018. PMID: 30189190 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike traditional chemotherapeutic agents, ICIs work by boosting the body's natural tumor killin …
Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been shown to improve survival in advanced non-small …
Cannabis-based medicines and medical cannabis for adults with cancer pain.
Häuser W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA. Häuser W, et al. Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD014915. doi: 10.1002/14651858.CD014915.pub2. Cochrane Database Syst Rev. 2023. PMID: 37283486 Free PMC article. Review.
There was low-certainty evidence that a synthetic THC analogue (nabilone) delivered over eight weeks was not superior to placebo in reducing pain associated with chemotherapy or radiochemotherapy in people with head and neck cancer and non-small cell lung can …
There was low-certainty evidence that a synthetic THC analogue (nabilone) delivered over eight weeks was not superior to placebo in reducing …
Zimberelimab: First Approval.
Markham A. Markham A. Drugs. 2021 Nov;81(17):2063-2068. doi: 10.1007/s40265-021-01628-5. Drugs. 2021. PMID: 34709602 Review.
Zimberelimab (()) is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lun …
Zimberelimab (()) is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus …
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y, Gao M, Huang Z, Yu J, Meng X. Chen Y, et al. J Hematol Oncol. 2020 Jul 28;13(1):105. doi: 10.1186/s13045-020-00940-z. J Hematol Oncol. 2020. PMID: 32723363 Free PMC article. Review.
Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non- …
Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have …
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Shaw AT, et al. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
We investigated the antitumour activity and safety of lorlatinib in advanced, ROS1-positive non-small-cell lung cancer (NSCLC). METHODS: In this open-label, single-arm, phase 1-2 trial, we enrolled patients (aged 18 years) with histologically or cytolo …
We investigated the antitumour activity and safety of lorlatinib in advanced, ROS1-positive non-small-cell lung cancer …
1,048 results